lundi 18 septembre 2017

Onco Actu du 18 septembre 2017

2. Etiologie

Tattoo ink particles can spread into lymph nodes [NHS Choices]

3.1 Prévention - Tabac

American Cancer Society Statement on Philip Morris International Support of New Effort [ACS]

4.7 Dép., diag. & prono. - Col de l'utérus

FDA Finalizes HPV Diagnostic Study Guidance [RAPS]

5. Traitements

Tumour bacteria sabotage chemotherapy by destroying cancer drugs [New Scientist]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology [BMS]

Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take [Forbes]

5.12.2 Immunothérapies - CAR-T

Mustang ties the knot with Fred Hutch on next-gen CAR-T for lymphoma [EndPoints]

5.12.4 Immunothérapies - Essais

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths [EndPoints]

5.12.7 Immunothérapies - vaccins

Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of Prostvac in Metastatic Prostate Cancer [Bavarian Nordic]

Bavarian Nordic tanks after Bristol-Myers-partnered vaccine flunks phase 3 prostate cancer trial [FierceBiotech]

Biotech's Cancer-Vaccine Insanity [Bloomberg]

5.2 Pharma

Xtandi's new Prosper trial win has Pfizer and Astellas eyeing a bigger market [FiercePharma]

5.3.4 Traitements - AMM (FDA, EMA)

Bayer receives FDA approval for Copanlisib in adults with relapsed follicular lymphoma after two prior systemic therapies [Bayer]

FDA approves first biosimilar for the treatment of cancer [FDA]

TESARO Receives Positive CHMP Opinion for ZEJULA® [Tesaro]

Bayer gears up to take on Gilead in lymphoma with Aliqopa green light [FiercePharma]

Tesaro earns CHMP thumbs-up for Zejula as three-way PARP race heats up [FiercePharma]

FDA approves new treatment for adults with relapsed follicular lymphoma [FDA]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017 [EMA]

U.S. FDA approves Bayer drug to treat follicular lymphoma [Reuters]

U.S. FDA approves biosimilar version of cancer drug Avastin [Reuters]

Bayer boosted as FDA OKs its PI3K drug Aliqopa for relapsed follicular lymphoma patients [EdPoints]

FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian Cancer [NCI]

Tesaro's ovarian cancer drug gets EU agency backing [Reuters]

5.4 Traitements - Economie

Perspectives on Cancer Drug Development Costs in JAMA [Harvard - Bill of Health]

6. Lutte contre les cancers

The Week My Husband Left And My House Was Burgled I Secured A Grant To Begin The Project That Became BRCA1 [Huffington Post]

Living With Cancer: The Crisis in Gynecological Cancer Research [NY Times]

6.1 Observation

Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts [CDC]

6.5 Médecines alternatives

Rigvir: Another unproven and dubious cancer therapy to be avoided [Science-Based Medicine]

6.6 Publications

Peer review in the ORCID community [ORCID]

Project to “fact check” genetic studies leads to three more retractions. And it’s just getting started. [Retraction Watch]

6.7 DMP, Big Data & applis

Who Will Build the Health-Care Blockchain? [MIT Technology Review]

6.7.3 DMP

With New Software, Epic Aims to Help Patients Share Health Records [Xconomy]